https://www.live-feeds.com/feed/why-lilly-and-novo-are-betting-on-amylin-to-power-a-new-wave-of-obesity-drugs-after-glp-1sContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/why-lilly-and-novo-are-betting-on-amylin-to-power-a-new-wave-of-obesity-drugs-after-glp-1shttps://www.live-feeds.com/feed/why-lilly-and-novo-are-betting-on-amylin-to-power-a-new-wave-of-obesity-drugs-after-glp-1s#u101583Mon, 05 Oct 2026 05:47:42 +0000Eli Lilly and Novo Nordisk are developing amylin-targeting drugs to treat obesity and diabetes, positioning amylin as a biological lever to complement or follow GLP-1 therapies. Recent data for the amylin-based drug petrelintide shows patients can lose more than 10% of their body weight with fewer side effects than current incretin-based drugs. Separately, Lilly is advancing retatrutide, a triple agonist that has delivered substantial weight loss and A1C reduction in trials for people with obesity and type 2 diabetes.Why it mattersThe pharmaceutical industry is seeking ways to increase weight